ReviewImpact of Genetic Polymorphisms in CYP2C9 and CYP2C19 on the Pharmacokinetics of Clinically Used Drugs
References (110)
- et al.
A 2.4- megabase physical map spanning the CYP2C gene cluster on chromosome 10q24
Genomics
(1995) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences
J. Biol. Chem.
(1992)- et al.
Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin
Drug Metab. Pharmacokinet.
(2010) - et al.
Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms
Biochem. Biophys. Res. Commun.
(2002) - et al.
Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes
Diabetes Res. Clin. Pract.
(2006) - et al.
Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards
Pharmacol. Res.
(2009) - et al.
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
J. Biol. Chem.
(1994) - et al.
The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects
J. Thromb. Haemost.
(2008) - et al.
Pharmacogenomics ofclopidogrel: evidence and perspectives
Thromb. Res.
(2011) - et al.
Identification and partial characterization of a novel CYP2C9 splicing variant encoding a protein lacking eight amino acid residues
Drug Metab. Pharmacokinet.
(2007)
Effect of the CYP2C9*3 allele on lornoxicam metabolism
Clin. Chim. Acta
(2006)
Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes
Drug Metab. Pharmacokinet.
(2010)
Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram
Eur. J. Pharmacol.
(2010)
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
J. Thromb. Haemost.
(2007)
Effects of the CYP2C19 genotype and cigarette smoking on the single oral dose pharmacokinetics and pharmacodynamics of estazolam
Prog. Neuropsychopharmacol. Biol. Psychiatry
(2003)
Summary of information on human CYP enzymes: human P450 metabolism data
Drug Metab. Rev.
(2002)
Pharmacogenomics: translating functional genomics into rational therapeutics
Science
(1999)
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
Br. J. Clin. Pharmacol.
(1998)
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians
J. Pharmacol. Exp. Ther.
(1994)
Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors
Drug Metab. Rev.
(1997)
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
Pharmacogenetics
(1996)
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
Pharmacogenetics
(1994)
Genetic association between sensitivity to warfarin and expression of CYP2C9*3
Pharmacogenetics
(1997)
Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication
Ther. Drug Monit.
(2000)
Biochemistry and molecular biology of the human CYP2C subfamily
Pharmacogenetics
(1994)
The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase
Pharmacogenetics
(1997)
CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates
Pharmacogenetics
(2000)
Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus
Pharmacogenetics
(2000)
Functional impact of CYP2C9*5, CYP2C9* 6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans
Clin. Pharmacol. Ther.
(2004)
CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population
Pharmacogenet. Genomics
(2005)
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans
Mol. Pharmacol.
(2001)
Identification ofa null allele ofCYP2C9 in an African-American exhibiting toxicity to phenytoin
Pharmacogenetics
(2001)
The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics
Epilepsia
(1998)
Discovery of new potentially defective alleles of human CYP2C9
Pharmacogenetics
(2004)
Identification of a novel variant CYP2C9 allele in Chinese
Pharmacogenetics
(2004)
Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes
Xenobiotica
(2009)
Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms
Clin. Pharmacol. Ther.
(2004)
Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin
J. Pharmacokinet. Pharmacodyn.
(2010)
Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes
Pharmacogenetics
(1998)
Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes
Clin. Pharmacol. Ther.
(1998)
The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects
Br J. Clin. Pharmacol.
(2005)
Inter-individual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9
Clin. Pharmacol. Ther.
(2009)
Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (—)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers
Clin. Pharmacol. Ther.
(2003)
Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes
Clin. Pharmacol. Ther
(2002)
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers
Clin. Pharmacol. Ther
(2002)
Genetic variation at the CYP2C locus and its association with torsemide biotransformation
Pharmacogenomics J.
(2007)
Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites
Pharmacogenetics
(2003)
CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians
Clin. Pharmacol. Ther
(2004)
Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects
Eur. J. Clin. Pharmacol.
(2011)
The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations
Personalized Med
(2004)
Cited by (99)
A genome-wide association study of 24-hour urinary excretion of endocrine disrupting chemicals
2024, Environment InternationalThe effects of estrogen on targeted cancer therapy drugs
2022, Pharmacological ResearchTargeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole – A probe drug of CYP2C19 metabolism
2022, Biomedicine and PharmacotherapyAssessment of susceptibility to phthalate and DINCH exposure through CYP and UGT single nucleotide polymorphisms
2022, Environment International
Copyright © 2013 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.